Moist wound dressing for chronic wound treatment now available in Germany
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Subscribe To Our Newsletter & Stay Updated